Classification and Pathology of Lung Cancer
- PMID: 27261908
- DOI: 10.1016/j.soc.2016.02.003
Classification and Pathology of Lung Cancer
Abstract
Advancement in the understanding of lung tumor biology enables continued refinement of lung cancer classification, reflected in the recently introduced 2015 World Health Organization classification of lung cancer. In small biopsy or cytology specimens, special emphasis is placed on separating adenocarcinomas from the other lung cancers to effectively select tumors for targeted molecular testing. In resection specimens, adenocarcinomas are further classified based on architectural pattern to delineate tissue types of prognostic significance. Neuroendocrine tumors are divided into typical carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma based on a combination of features, especially tumor cell proliferation rate.
Keywords: Classification; Immunohistochemistry; Lung cancer; Molecular testing; Pathology.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Small Biopsy and Cytology of Pulmonary Neuroendocrine Neoplasms: Brief Overview of Classification, Immunohistochemistry, Molecular Profiles, and World Health Organization Updates.Adv Anat Pathol. 2022 Nov 1;29(6):329-336. doi: 10.1097/PAP.0000000000000360. Epub 2022 Sep 2. Adv Anat Pathol. 2022. PMID: 36053019 Review.
-
Clinical implications of lung neuroendocrine neoplasm classification.Expert Rev Anticancer Ther. 2021 Apr;21(4):377-387. doi: 10.1080/14737140.2021.1862654. Epub 2020 Dec 24. Expert Rev Anticancer Ther. 2021. PMID: 33306420 Review.
-
Two cases of lung neuroendocrine carcinoma with carcinoid morphology.Diagn Pathol. 2019 Sep 12;14(1):104. doi: 10.1186/s13000-019-0886-1. Diagn Pathol. 2019. PMID: 31511024 Free PMC article.
-
[Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].Pathologe. 2015 May;36(3):283-92. doi: 10.1007/s00292-015-0030-2. Pathologe. 2015. PMID: 25956813 Review. German.
-
Bronchopulmonary carcinoid tumors--a significant diagnostic problem.Rocz Akad Med Bialymst. 1997;42 Suppl 1:146-61. Rocz Akad Med Bialymst. 1997. PMID: 9337533 Review.
Cited by
-
Hepcidin Upregulation in Lung Cancer: A Potential Therapeutic Target Associated With Immune Infiltration.Front Immunol. 2021 Apr 1;12:612144. doi: 10.3389/fimmu.2021.612144. eCollection 2021. Front Immunol. 2021. PMID: 33868231 Free PMC article.
-
Prolyl hydroxylase domain enzyme PHD2 inhibits proliferation and metabolism in non-small cell lung cancer cells in HIF-dependent and HIF-independent manners.Front Oncol. 2024 Jun 27;14:1370393. doi: 10.3389/fonc.2024.1370393. eCollection 2024. Front Oncol. 2024. PMID: 39007099 Free PMC article.
-
Palliative Care as an Adjunct to Standard Pulmonary Rehabilitation: A Pathway To Improving Functional Independence & Quality of Life in a Patient With Lung Cancer.Cureus. 2022 Aug 30;14(8):e28580. doi: 10.7759/cureus.28580. eCollection 2022 Aug. Cureus. 2022. PMID: 36185837 Free PMC article.
-
Protein Kinase C as a Therapeutic Target in Non-Small Cell Lung Cancer.Int J Mol Sci. 2021 May 24;22(11):5527. doi: 10.3390/ijms22115527. Int J Mol Sci. 2021. PMID: 34073823 Free PMC article. Review.
-
LINC01140 promotes the progression and tumor immune escape in lung cancer by sponging multiple microRNAs.J Immunother Cancer. 2021 Aug;9(8):e002746. doi: 10.1136/jitc-2021-002746. J Immunother Cancer. 2021. PMID: 34446576 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical